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Abnormalities of T-cell subsets in glomerulonephritis and systemic
lupus erythematosus. In this study, three kinds of monoclonal antibodies
directed at human T lymphocytes, produced by mouse hybridomas and
termed OKT3, OKT4, and OKT8, were used in an indirect immunofluo-
rescence assay, to analyze the distribution of peripheral T lymphocyte
subsets in 41 patients with glomerulonephritis (GN) and 11 patients with
systemic lupus erythematosus (SLE). As assessed by functional stud-
ies, OKT4 and OKT8 defined the helper and cytotoxic/suppressor T
lymphocytes subsets, respectively, whereas OKT3 recognized all pe-
ripheral T-cells. Among GN patients, the ones presenting membranous
GN (MGN), IgA disease, and lipoid nephrosis associated with segmen-
tal and focal hyalinosis (FGS) showed a significant decrease of their
peripheral cytotoxic/suppressive T cells. On the contrary, no significant
alteration was found in the peripheral T-cell distribution of patients with
membranoproliferative GN (MPGN) and lipoid nephrosis associated
with minimal-change GN (MCGN). Unexpectedly, there was a tenden-
cy for peripheral cytotoxic/suppressive T lymphocytes to be high in the
majority of SLE patients, and only two of these subjects exhibited a
relative decrease in peripheral OKT8 marked cells. The steroid therapy
received by our patients might account for this discrepancy with
previous reports of altered suppressor function in active SLE.
Anomalies des sous-populations de cellules T dans les glomerulone-
phrites et le lupus erythemateux dissemine. Dans cette étude, trois sortes
d'anticorps monoclonaux OKT3, OKT4, et OKT8 produits par des
hybridomes de souris et dirigés contre des lymphocytes T humains, ont
été utilisés dans un test d'immunofluorescence indirecte pour analyser
Ia distribution des cellules T periphériques chez 41 sujets atteints de
glomérulonéphrite (GN) et 11 sujets avec lupus érythémateux disséminé
(SLE). Les anticorps OKT4 et OKT8 définissent les sous-populations
de lymphocytes T helper et suppresseurs respectivement, tandis que
l'anticorps OKT3 reconnait toutes les cellules T périphériques. Les
patients présentant une glomérulonéphrite extramembraneuse (MGN),
une maladie a dépôts intercapillaires d'IgA ou une néphrose lipoidique
associée a une hyalinose segmentaire et focale (FGS) avaient une
diminution significative du nombre des cellules T suppressives pen-
pheriques. Inversement, aucune alteration significative n'a été trouvée
dans Ia distribution des cellules T péniphériques chez les malades
présentant une glomerulonephrite membranoproliferative (MPGN) ou
une nephrose lipoidique associée a des lesions glomerulaires minimes
(MCGN). Chez Ia plupart des malades atteints de lupus erythemateux le
pourcentage de lymphocytes T cytotoxiques/suppresseurs périphC-
riques était élevé et seuls deux de ces malades ont présente une
diminution relative du nombre de cellules marquees par l'anticorps
OKT8. La corticothérapie recue par ces sujets peut être responsable de
Ia difference entre ces résultats et les nombreux travaux en faveur d'une
alteration de Ia fonction suppressive dans le lupus.
Effector lymphocytes mediating immune responses, antibody
production, or cell-mediated immunity are controlled by regula-
tory mechanisms involving complex macrophage-lymphocyte
interactions where subsets of regulatory T cells play a central
role. As suggested by experimental models and clinical obser-
vations, glomerulonephritis could result from a transient or
permanent dysregulation of the control of immune responses
leading to immune complex deposition and/or autoantibody
production [1]. Failure of regulatory mechanisms may lead to
abnormal immune responses to antigenic stimulus and/or to the
development of autoimmunity.
In man, different approaches are available to evaluate T-cell
subsets. Until recently, the most commonly used methods dealt
with the identification of receptors for the Fc fragment of
immunoglobulins G and M [2] and various functional assays of
T-cell helper or suppressor activities that regulate some in vitro
immune responses. These methods have been used to explore
the regulatory mechanisms of immunity in normal subjects and
in various pathologic conditions, including systemic lupus ery-
thematosus and to a more limited extent primitive glomerulone-
phnitis.
A new insight to this problem has been derived from the use
of mouse hybridomas secreting monoclonal antibodies directed
against specific antigenic determinants of human T cells. Some
of these antibodies have been recently demonstrated to specifi-
cally recognize T-cell subsets committed to distinct functional
programs. In human peripheral blood, two main T-cell subpop-
ulations coexist. One is implicated in helper function and
lymphokine production, whereas the other includes T cells with
cytotoxic and suppressor activities [3, 4].
In the present study, monoclonal antibodies were used in an
indirect immunofluorescence assay to analyze the distribution
of the peripheral blood T-cell subsets in several types of
glomerulonephritis (GN) and in systemic lupus erythematosus
(SLE). Three kinds of monoclonal antibodies were used. These
antibodies, termed OKT3, OKT4, and OKT8, react with 95%,
60% and 30%, respectively, of the total T cell population. It has
been shown in functional studies that OKT4+ and OKT8+ cells
represent the human inducer (helper) and cytotoxic/suppressor
T lymphocyte subpopulations, respectively.
Methods
Patients. For this study 52 patients (26 males and 26 females)
who were followed up and whose renal biopsies were studied at
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Table 1. Clinic and laboratory data of glomerulonephritis patients
Hospital Necker, Clinique Néphrologique, between 1963 and
1980 were selected. The clinical and biological features of
individual patients are presented in Tables 1 and 2. According
to their diagnosis, patients were divided in two principal
categories:
The first one included 41 patients with different kinds of
idiopathic glomerulopathies (Table 1). These patients were
subdivided into four different groups according to immunohisto-
pathologic and electromicroscopic studies. Twelve of them
showed membranous glomerulonephritis (MGN), 10 showed
membranoproliferative glomerulonephritis (MPGN), 9 showed
glomerulonephritis with IgA intercapillary deposits (Berger's
disease), and 10 showed lipoid nephrosis. Among the latter, 6 of
the patients exhibited minimal-change glomerulonephritis
(MCGN); and 4, focal and segmental hyalinosis (FGS). All GN
were idiopathic except for one case of MPGN associated with a
mixed cryoglobulinemia (patient 17). The clinical presentation
at the moment of diagnosis was in all cases the typical one for
Patient Renal biopsy Creatininemia Proteinuria Hyper- Hema- Duration of
no. Age/sex diagnosis mg/liter g/day tension tuna illness
1
2
3
4
5
6
7
8
9
10
11
12
56/M
62/M
42/F
52/F
46/F
38/F
85/F
23/F
47/F
63/F
21/F
25/M
Group 1: Membranous glomerulonephritis (MGN)
MGN.type 11-Ill 8 0.60
MGN.type II 14 0.15
MGN.type II 10 0.15
MGN 12 2.00
diffuse MGN 11 3.00
diffuse MGN 8 2.80
MGN 12 1.00
MGN.type II 10 0.40
MGN.type I-Ill 10 6.30
diffuse MGN 60 1.00
diffuse MGN 10 0.30
MGN 8 0.40
—
—
—
+
—
—
—
—
+
+
—
—
—
—
—
—
—
—
—
—
—
—
—
—
6 months
12 months
16 months
5 years
20 months
12 years
9 years
5 years
9 years
II years
12 months
9 years
13
14
15
16
17
18
19
20
21
22
37/F
69/F
26/M
31/F
67/M
32/M
58/M
50/M
27/F
28/F
Group 2: Membrano-proliferative glomerulonephritis (MPGN)a
MPGN+ 10 1.60
MPGN+++ 10 1.30
MPGN+++ 47 10.00
MPGN++ 50 0.15
MPGN+ 18 0.15
MPGN+ 21 14.00
MPGN+++ 64 1.00
MPGN+ 20 0.15
MPGN++ 10 0.50
MPGN++ 6 1.60
—
—
—
+
—
+
+
—
—
—
+
+
+
+
+
+
+
+
—
—
6 months
3 months
6 years
7 years
4 years
10 years
4 months
2 years
2 years
3 years
23
24
25
26
27
28
29
30
31
23/M
20/M
39/F
35/M
28/M
35/M
38/M
46/F
28/F
Group 3: IgA Disease'
MES.PGN+++ 9 0.90
MES.PGN++ 11 0.36
MES.PGN+ 7 0.45
MES.PGN++ 10 1.00
MES.PGN++ 11 3.00
MES.PGN+ 12 0.15
MES.PGN+ 8 1.00
MES.PGN++ 9 1.00
MES.PGN+ 7 0.15
+
—
—
—
—
+
—
—
+
—
—
+
+
+
+
+
+
—
7 years
4 years
5 years
9 years
14 months
3 years
3 years
20 years
11 years
32
33
34
35
36
37
35/F
23/M
17/M
43/M
32/M
47/M
Group 4: Lipoid nephrosisa
(a) With minimal change lesions
MCGN+ 13 4.00
MCGN+ 8 5.00
MCGN+ 8 0.15
MCGN+ 10 0.15
MCGN+ 10 0.15
MCGN++ 25 0.15
3 months
12 months
3 years
27 years
10 months
7 years
38
39
40
41
51/F
46/M
52/M
21/M
(b) With focal and segmental glomerular sclerosis
FGS++ 7 3.50
FGS++ 14 1.20
FGS± 18 15.00
FGS++ 93 7.60
2 months
7 years
6 years
3 years
All the forms were classified according to the lesions present on biopsy sections as +, + +, and + + + in increasing order of severity.
MES.PGN is mesangial proliferative GN.
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Table 2. Clinic and laboratory characteristics of patients with systemic lupus erythematosus
Prednisone
Patient
no. Age/Sex
Renal biopsy
diagnosisa Clinical involvement Anti-DNA
therapy Duration of
mg/day illness
14/F MES-PGN Articular, cutaneous, renal, pericardial 20% — 6 years2 38/F ND Cutaneous, articular 34% 10—20 2 years
3 37/F ND Hematologic, articular, renal 20% 10—20 22 years
4 25/F MGN Cutaneous, renal, systemic symptoms 20% 20—40 9 months
5 21/F MGN + MES-PGN Cutaneous, articular, renal 20% 10—20 3 years
6 45/F MPGN Articular, renal, cutaneous 20% 10—20 9 years
7 49/F ND Cardiovascular, neurologic, hematologic, renal 40% 30 17 years
8 43/F MPGN Cutaneous, renal, articular 20% 10 23 years
9 24/F MGN Pericardial, cutaneous, articular, renal 27% 15 13 years
10 25/F MPGN Renal, cutaneous, articular 60% — 4 years
11 38/F MPGN Cutaneous, renal 13% — 7 years
a Abbreviations are MES-PGN, mesangioproliferative glomerulonephritis; ND, not done; MGN, membranous GN; MPGN, membrano-
proliferative GN.
Table 3. Clinic and laboratory data of non-glomerulonephritis patients
Serum
Age creatinine
Patient no. Diagnosisa yr Sex mg/liter OKT4+/OKT8+
1 Persistent proteinuria 35 M 20 1.3
2 Persistent proteinuria 31 M 10 1.9
3 Persistent proteinuria 23 F 10 1.3
4 Nephrosclerosis 48 M 20 1.9
5 ACIN 55 F 22 1.4
6 ACIN 35 F 24 2.0
7 ACIN 43 F 52 1.5
8 CR1 80 F 14 1.6
9 HNS 45 F 14 1.6
10 HNS 43 F 9 2.0
11 Severe HNS 33 M 9 1.7
12 CPN 40 M 26 1.3
a Abbreviations are ACIN, analgesics chronic interstitial nephritis; CR1, chronic renal insufficiency; HNS, hypertensive nephrosclerosis; CPN,
chronic pyelonephritis.
each group of disease. Nephrotic syndrome with edema, pro-
teinuria, and hypoalbuminemia was present in lipoid nephrosis
patients. In MPGN, hematuria was commonly found. Patients
with IgA disease had macroscopic or microscopic hematuria
and proteinuria as the clinical presentation. Acute episodes
were sometimes correlated with sore throats. The only particu-
lar feature of MCGN patients was that 4 of them (patients 33 to
36) were being treated with corticosteroids (1 mg/kg/day pred-
nisolone) for their nephrotic syndrome when the test was
performed.
The second category included 11 systemic lupus erythemato-
sus (SLE) patients exhibiting two or more systemic manifesta-
tions of the disease (Table 2). Seven of them had a biopsy
confirmation of their renal involvement. In patient 7, renal
biopsy was not performed; nevertheless, there were clinical
signs of renal involvement such as proteinuria, edema, and a
serum creatinine value of 30 mg/liter. All patients were treated
with corticosteroids except patient 10, a 25-year-old woman
who had a highly evolving form of SLE recently diagnosed. The
renal biopsy in this case showed a particularly severe type of
membranoproliferative glomerulonephntis with numerous fi-
brotic scars. The biological signs of the disease were also very
prominent as assessed by anti-DNA antibodies.
Controls. Blood samples from 27 healthy donors were ob-
tained as normal controls. Twelve additional subjects with
different types of nonglomerular renal diseases (non-GN pa-
tients) and varying degrees of chronic renal failure were stud-
ied. Their data are summarized in Table 3. The ages were well
matched in patients and control subjects.
Renal biopsy. Immunohistologic studies of renal specimens
were obtained in all GN patients and 6 of the SLE patients.
Electromicroscopy was also performed when necessary. All
staining methods were previously described by Noel et al [5].
Antibodies. Monoclonal antibodies, termed OKT3, OKT4,
and OKT8 (provided by P. C. Kung and G. Goldstein, Ortho
Pharmaceutical Corporation, Raritan, New Jersey) were pro-
duced and characterized as already described [6]. Briefly, after
i.p. immunization of BALB/cJ or CAF1 mice, with either E-
rosette peripheral T cells or thymocytes, the spleen was re-
moved, and a single-cell suspension was prepared. Cell fusion
between splenocytes and P3 x63AgUI myeloma cells was then
carried out. After several weeks, the supernatants from cultures
containing hybridomas were tested on normal peripheral lym-
phocytes by means of indirect immunofluorescence tests. Hy-
bridoma cultures containing the specific antibodies were
cloned. The clones were then transferred i.p. into CAF1 mice,
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ferred i.p. into CAF1 mice, and the resulting malignant ascite
was used for the lymphocyte characterization.
OKT3 [7] reacted with 95% of the E-rosetting cell population,
and OKT4+ [8] and OKT8+ [9] cells represented 65% and 34%,
respectively, of peripheral T cells. According to their functional
properties, OKT4+ and OKT8+ cells represent the helper
(inducer) and the cytotoxic/suppressor T lymphocyte subpopu-
lations, respectively.
For the immunofluorescence assay, goat antimouse IgG
antibodies were obtained from complete serum (Miles Labora-
tories) following absorption on a human IgG-coupled Sepharose
4B column, and subsequent purification on a mouse IgO-
coupled Sepharose 4B column. Purified antibodies were then
conjugated to FITC [10].
Indirect immunofluorescence assay for T lymphocyte subset
identification. Ten milliliters of venous heparinized blood were
diluted and layered over a Ficoll-Telebrix density gradient. All
blood samples were processed for the immunofluorescence
assay on the same day of collection. After centrifugation, the
interface layer containing lymphocytes was washed twice in
Hanks balanced salt solution (HBSS), and the cell count was
adjusted to 10 to 20 x 106 cells/mi; 45 l of the lymphocyte
suspension were placed in each of three tubes. The tubes were
then incubated for 30 mm at 4° C with 5 p.l of appropriate
dilutions of OKT3, OKT4, and OKT8 antibodies.
After incubation, the cells were washed twice in cold HBSS
containing 5% fetal calf serum and 0.2% sodium azide. Lym-
phocytes were then labeled with 50 pA of fluoresceinated goat
antimouse IgG for 30 mm at 4° C, washed twice in cold medium,
resuspended gently with a Pasteur pipette, and one drop
examined with a Leitz Orthoplan microscope.
Approximately 200 cells per slide were counted. The results
were expressed as the percentage of each T-cell subset with
respect to the total number of mononuclear cells present in each
field. The ratio between OKT4 and OKT8 stained T cell
percentages was then deduced, and used as the index of the test
results in each subject. Thus, errors of interpretation due to
different cell separation conditions even between normal sub-
jects can be eliminated. When duplicate samples of some
patients or controls were done, the results obtained agreed
within 5% with preceding values.
Statistical analysis. Mean comparisons were performed by
the Student t test.
Results
T lymphocyte subsets in control populations. The percentage
values obtained in this study for the different T-cell subsets in
normal controls and non-GN patients are detailed in Table 4. In
most subjects, the OKT4+/OKT8+ ratio ranged between 1 and
2. Some difference was found when comparing the two control
populations. The percentual values of OKT4+ and OKT8+ T-
cell subsets were significantly higher (<0.001 and <0.05, re-
spectively) in non-GN patients when compared with normal
controls. Nevertheless, the OKT4+/OKT8+ ratio did not differ
in both groups.
T lymphocyte subsets in patients with GN. Results obtained
in these patients are presented in Table 5 and in Fig. 1. In the
membranous GN group, patients exhibited a significant in-
crease in their OKT4+/OKT8+ ratio with respect to the value
encountered in normal controls (P < 0.001) and non-ON
patients (P < 0.002). This increase was mainly due to a
reduction in OKT8-marked T-cell percentage when compared
either with normal controls (P <0.001), or non-GN patients (P
<0.001).
Patients with Berger's disease also had an increased mean
OKT4+/OKT8+ ratio (normal controls, P < 0.001; non-GN
patients, P < 0.02). As with MGN patients, OKT8+ T-cell
subset was significantly decreased in this group of patients
when compared with normal subjects (P < 0.001) or non-ON
patients (P < 0.01).
The MPGN group of patients showed a significant decrease in
their percentage OKT8+ T-cell subset value, only with respect
to the non-GN-patient mean value (P <0.05). This could be
explained by the difference between the mean values for the
two control populations mentioned above. Nevertheless, their
OKT4+/OKT8+ ratio was in the normal range.
For patients with lipoid nephrosis, all the parameters corre-
sponding to the group of patients with MCGN were in the
normal range of values, Among the patients with FGS, 2 of the 4
patients presented an OKT4+/OKT8+ ratio of 3,4 and 4.4, thus
showing prevalence on the inducer (helper) population in their
peripheral T lymphocyte distribution.
T lymphocyte subsets in patients with SLE. The percentage
values encountered in the cell counts of SLE patients are shown
in Table 6. No obvious correlation was found between clinical
or biological features (Table 2) and T-cell pattern. In particular,
the only two patients with increased OKT4/OKT8 ratio did not
show particularly severe disease.
Discussion
Insights into the pathogenesis of primary or idiopathic GN
have been provided by data obtained both from experimental
animal models and the continuously increasing repertory of
serologic and immunohistologic diagnostic methods. Most of
the reports on immunologic dysfunction in GN patients are
focused on abnormalities of the humoral efferent limb of the
immune system. The deposition of circulating immune com-
plexes [11], or their in situ formation [12, 131, is considered the
commonest pathogenetic mechanism in GN. This physiopatho-
logic hypothesis for GN is supported by various experimental
models, where the pathogeneic role of immune complexes has
been clearly established [11, 14—17]. Moreover, in man, differ-
ent antigenic exogenous or endogenous agents have been
shown to induce glomerular lesions similar to those observed in
experimental models. These agents include infectious antigens
[18—20], tumor antigens [21, 22], and chemical haptens [23—25].
Circulating immune complexes have been often found in ON
patients [26], although some negative results have been report-
ed [27, 28]. Unfortunately, in the majority of human GN,
although immune deposits are frequently found in the glomeru-
Ii, the causal antigen cannot be identified; sometimes only
indirect biological evidence suggests that an antigenic challenge
had occurred [29]. Concerning abnormalities of cellular immu-
nity in GN patients, it was reported that some subjects may
show evidence of a hypersensitivity state against glomerular
[30] or infectious antigens [31]. Moreover, in some cases, the
presence of a nephrotic syndrome was attributed to an abnor-
mal production by Con A-activated lymphocytes of a vascular
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Table 4. Mean percentage values of peripheral blood T-lymphocyte subsets in control populationsa
OKT3+ cells OKT4+ cells OKT8+ cells
% % OKT4+/OKT8+
Nonglomerulonephritis
patients 67.85 3.21 52.12 2.54 31.57 1.77
Normal subjects 68.44 1.68 41.16 1.49 26.84 1,21
1.62 0.07
1.61 0.09
Values are the means SEM.
Table 5. Peripheral lymphocytes counts and percentages of T-cell subsets in glomerulonephritis patients
Lymphocytes OKT3+ cells OKT4+ cells OKT8+ cells
Patient no. per mm3 % % OKT4+/OKT8+
Group 1: Membranous glomerulonephritis
1 2910 38.5 34.2 8.7 3.9
2 4032 76.9 47.8 31.7 1.5
3 1270 65,5 38.3 25.0 1.5
4 1008 60.8 51.9 28.6 1.8
5 940 57.7 43.2 9.9 4.3
6 1530 32.0 21.5 9.3 2.3
7 2979 63.9 36.9 10.8 3.4
8 1628 68.0 47.8 31.6 1.5
9 1460 46.6 34.2 17.0 2.0
10 1386 56.2 38.2 13.7 2.7
11 1650 91.4 63.5 19.8 3.2
12 1248 70.5 59.3 28.5 2.0
Mean SEM 60.7 4.7 43.1 3.4 19.6 2.6 2.5 0.3
Group 2: Membranoproliferative glomerulonephritis
13 2280 75.0 55.4 26.4 2.1
14 1116 83.0 80.7 16.8 4.8
15 2063 60.0 29.4 26.0 1.1
16 1404 72.0 52.3 28.0 1.8
17 1700 24.1 11.9 7.0 1.7
18 2223 84.0 61.9 35.0 l.7
19 1890 49.2 41.9 18.9 2.2
20 2691 80.3 54.1 31.5 1.7
21 2060 77.5 45.2 26.5 1.7
22 2153 71.4 58.5 26.1 2.2
Mean SEM 67.7 5.9 49.1 5.9 24.2 2.5 2.1 0.3
Group 3: IgA disease
23 1595 70.7 36.2 27.3 1.3
24 2204 68.7 37.5 21.8 1.7
25 1100 51.8 39.4 18.2 2.1
26 1785 80.9 75.8 25.9 2.9
27 2304 49.1 28 19.8 1.4
28 2244 78.0 53.7 12.9 4.1
29 1848 81.0 70.9 19.6 3.6
30 2538 71.5 52.1 21.0 2.5
31 2120 64.7 46.2 31.6 1.4
Mean SEM 68.5 3.9 48.9 5.4 22.0 1.8 2.3 0.3
Group 4: Lipoid nephrosis(a) With minimal change lesions
32 1380 52.6 23.7 15.3 1.5
33 1570 75.1 51.9 22.9 2.3
34 1664 72.1 57.6 35.1 1.6
35 2380 57.2 31.1 19.8 l.5
36 1430 76.7 50.7 39.9 1.3
37 3087 71.0 44.3 24.1 1.8
Mean SEM 67.5 4.1 43.2 5.4 26.2 3.8 1.7 0.1
(b) With focal and segmental glomerular sclerosis
38 1281 80.6 73.6 21.1 3.4
39 1953 75.9 50.0 40.9 1.2
40 1809 80.0 56.2 12.7 4.4
41 1785 83.6 42.7 33.8 1.2
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Normal Non-GN MPGN MGN I9AGN FGS MCGN
controls
Fig. 1. Representation of OKT4+IOKT8+ ratios in patients with
glomerulonephritis and in control subjects. The shaded area represents
the mean SD of the normal controls. Abbreviations are GN, glomeru-
lonephritis; MPGN, membranoproliferative GN; MGN, membranous
GN; FGS, focal glomerulosclerosis; MCGN, minimal-change ON.
permeability factor [32]. The aim of the present study was to
define, by means of specific monoclonal antibodies, the distri-
bution of the two main T-cell subsets (helper OKT4+ and
cytotoxic/suppressor OKT8+) among peripheral blood lympho-
cytes from ON and SLE patients. In fact, a putative dysregula-
tion of immune responses could possibly be reflected by an
imbalance between regulatory T cell subsets. Indeed, patients
with MON and Berger's disease showed an increased OK-
T4+/OKT8+ ratio, suggesting a relative prevalence of the
helper T-cell population over that of suppressor T cells. These
types of GN are the ones where considerable evidence favors
the hypothesis of a sustained immune stimulation [33, 34]. In
addition, an abnormal immune response in MGN was recently
described by Ooi et al [35]. These authors found in MGN
patients a decreased 1gM and IgG production by polyclonally
activated B lymphocytes. This finding is not in contrast with
our results, because the decrease in antibody production was
attributed in those patients to the presence of a monocyte
population with suppressor activity and not to an increased
activity of suppressor T lymphocytes. Moreover, polyclonal
activation of B lymphocytes may not exactly reflect B-cell
responses to a precise antigen.
In IgA nephropathy, a decrease in IgA-specific suppressor T-
cell activity has been described [36]. This finding correlates well
with the augmented OKT4+IOKT8+ ratio we found in these
patients. In patients presenting lipoid nephrosis associated with
minimal change lesions, no abnormality was found in the
distribution of their peripheral lymphocytes. Nevertheless,
abnormalities of T-cell function were reported [37], and it was
seen that a deficiency of cell-mediated immunity spontaneously
associated with measles infection or induced by immunosup-
pressive drugs leads to the remission of the nephrotic syndrome
associated with MCGN [38]. On the contrary, 2 of the 4 patients
exhibiting focal and segmental hyalinosis showed an increased
OKT4+/OKT8+ ratio. These results need further confirmation
especially because of the small number of patients tested.
Nevertheless, an enhancement of the immune response may
exist in this form of lipoid nephrosis, which could explain the
different clinical course of those patients with respect to MCGN
subjects. In addition, this observation points out that FGS may
represent an individual clinicopathologic entity, instead of
being simply an advanced form of MCGN as initially stated
[39].
Patients with MPGN showed a normal balance between
OKT4+ and OKT8+ peripheral T cells. These results might
suggest that, if some abnormalities of the immune system are
involved in the pathogenesis of the disease, they influence the
response to a restricted number of antigens. Thus, the abnor-
mality could not be detected by a global quantitative evaluation
of peripheral T-cell subpopulations. Alternatively, this form of
GN may result from a different pathogenic mechanism.
In addition, a single patient may exhibit temporal variations
in his immunologic status, which could more generally explain
the lack of concordance found between the severity of the
histologic lesions and the degree of the immunologic dysequili-
brium.
Still more surprising are the results obtained in SLE patients
who seemed to be the most susceptible to present a global
disorder of the regulation of immune response. Only 2 patients
had a relative decrease of the suppressor T-cell population. The
other patients, including the only one with active disease and no
treatment, tend to present with high numbers of peripheral
OKT8+ (cytotoxic/suppressor) T cells. One should note, how-
ever, that when tested, most patients were receiving mainte-
nance steroid therapy and did not show any sign of disease
activity.
Glomerular lesions in SLE and in murine lupus are caused by
immune complexes, some of them including autoantibodies and
Table 6. Peripheral lymphocytes counts and percentages of T-cell subsets in patients with systemic lupus erythematosus
Patient no.
Lymphocytes
per mm3
OKT3+
%
cells OKT4+
%
cells OKT8+
%
cells
OKT4+/OKT8+
1 2064 77.0 45.0 26.0 1.7
2 1100 72.0 39.3 30.1 1.3
3 1720 62.7 55.7 17.0 3.2
4 2352 58.1 38.0 31.1 1.2
5 1650 91.4 63.5 19.8 3.2
6 658 73.5 41.3 35.2 1.1
7 840 68.4 38.1 29.1 1.3
8 1344 46.9 15.0 28.0 0.5
9 2960 70.3 38.0 37.9 1.0
10 536 75.0 37.0 40.0 0.9
11 1435 53.8 32.0 26.4 1.2
Mean SEM 68.1 3.7 40.3 3.7 29.1 2.1 1.5 0.3
5
4
3
2
0
0
S
S
SS
.
0 0
S
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ies and autoantigens. But the physiopathology of the autoanti-
body production itself is yet unclear, and several hypotheses
have been put forward. Among them are viral infections,
antilymphocyte antibodies, abnormalities in regulatory T-cell
subsets, and intrinsic B-cell abnormalities [40]. In man and
mice, the conflicting results reported on a possible suppressor
T-cell deficiency in lupus {4l, 42] are likely due to the great
diversity of the techniques used to test the suppressive activity
in functional assays, and to the heterogeneity of mononuclear
cells expressing suppressive activity. Such cells include several
subsets of lymphocytes, monocytes [43], and in man the so-
called Ty cells [2].
Recently, this latter population was found to contain mostly
null cells and monocytes [44]. A recent study in man could not
demonstrate a suppressor T-cell deficit in an in vitro model of
antibody production towards the TNP-polyacrylamide antigen
but on the contrary, demonstrated a T helper-cell abnormality
[45]. Again, the dysregulation of the immune responses might
be restricted in SLE to a limited number of autoantigens or
xenoantigens, as is the case in the murine models of lupus.
Conclusion. The present work provides a new approach to
the problem of T-lymphocyte markers in some clinical situa-
tions by means of a simple immunofluorescence method. This
assay offers a useful but static picture of the immune T-cell
distribution in a given patient at a precise moment. Thus, the
discovery of a numerical imbalance among lymphocyte subsets
in different clinical situations, as presented above, represents
only a first step in the understanding of an immunologic
dysequilibrium. It will be necessary to perform functional in
vitro tests using the separated helper and suppressor T-cell
subsets to understand the real effect on the immune response of
such numerical abnormalities, even though the demonstration
in GN patients of an imbalance between helper and suppressor
T cells is in accordance with many of the preexisting etiopatho-
logic conceptions. In SLE, the corticoid therapy received by
most patients makes the interpretation of results difficult. More
longitudinal studies in homogeneous untreated populations,
testing different parameters in each subject, will be necessary to
conceal the different findings described in the literature. Such
extensive studies are required before discarding the hypothesis
of a dysregulation of the immune system operating at the
suppressor T-cell level.
Reprint requests to Dr. L. Chatenoud, Unite 25 INSERM. Hôpital
Necker, 161, rue de Sèvres, 75730 Paris, Cedex 25, France
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